UK drug development company ValiRx (AIM:VAL) has been in the headlines probably more than it would have liked since the beginning of November, when a trading update triggered a series of selloffs and a sharp decline in price.
The reaction, or possibly overreaction, has mostly removed the froth whipped up earlier this autumn after two private investors increased their holdings – one dutifully following it up on Twitter.
Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.
Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.
Free 28 day trial. Cancel anytime.
Log In or Sign Up to Armchair Trader+Already a member? Log in here:
Not a member? Sign up now or see the membership benefits
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.
